For Mytesi® product information, adverse event reports, and product complaint reports, please contact:
Napo Pharmaceuticals Customer Service
Phone: (844) 722-8256
Important Safety Information
Mytesi® (crofelemer 125 mg delayed-release tablets) is approved for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. Rule out infectious etiologies of diarrhea before starting Mytesi® in order to avoid the risk of potential worsening of disease due to delay of appropriate therapy. The most common adverse events (incidence ≥ 3%) reported in Mytesi® clinical trials were upper respiratory tract infection, bronchitis, cough, flatulence, and increased billirubin.
Please see further details and complete Prescribing Information available at Mytesi.com